Dabucon, Nereka M.
HRN: 25-35-45 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/17/2025
LEVOFLOXACIN 500MG (TAB)
01/17/2025
01/20/2025
PO
500 Mg
Q48 Hrs
Acute GN
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes